Variables |
Overall cohort (n = 103) |
Scanner Optima CT660 (n = 50) |
Scanner DiscoveryCT750 HD (n = 53) |
p value (scanner) |
Tube voltage 120 kVp (n = 51) |
Tube voltage 100 kVp (n = 52) |
p value (kVp) |
---|---|---|---|---|---|---|---|
Gender | |||||||
Male Female |
59 (57%) 44 (43%) |
28 (56%) 22 (44%) |
31 (58%) 22 (42%) | 0.798a |
33 (65%) 18 (35%) |
26 (50%) 26 (50%) | 0.131a |
Age | |||||||
Mean (median) IQR |
69.2 (70) (64–75) |
69.4 (70) (65–75.3) |
68.9 (69) (62–74.5) | 0.498c |
69.8 (70) (64–76) |
68.6 (68.5) (62–74.8) | 0.251c |
Side Right Left |
60 (58%) 43 (42%) |
31 (62%) 19 (38%) |
29 (55%) 24 (45%) | 0.454a |
31 (61%) 20 (39%) |
29 (56%) 23 (44%) | 0.606a |
Position Upper Medium Lower Mixed |
63 (64%) 1 (1%) 29 (30%) 5 (5%) |
33 (69%) 1 (2%) 13 (27%) 1 (2%) |
30 (60%) 0 (0%) 16 (32%) 4 (8%) | 0.360b |
30 (61%) 1 (2%) 16 (33%) 2 (4%) |
33 (67%) 0 (0%) 13 (27%) 3 (6%) | 0.731b |
Volume (cm3) | |||||||
Mean (median) IQR |
46.4 (39.1) (19.1–62.8) |
44.2 (40.6) (19–54.7) |
48.5 (38.1) (19.5–71.9) | 0.843c |
52.1 (42) (20.7–67.9) |
40.9 (36.7) (18.4–56.2) | 0.181c |
Histological type | |||||||
Adenocarcinoma Squamous cell carcinoma Neuroendocrine |
83 (82%) 16 (16%) 2 (2%) |
38 (78%) 10 (20%) 1 (2%) |
45 (87%) 6 (11%) 1 (2%) | 0.580b |
40 (78%) 9 (18%) 2 (4%) |
43 (86%) 7 (14%) 0 (0%) | 0.380b |
Previous therapy | |||||||
No Yes |
75 (74%) 26 (26%) |
38 (76%) 12 (24%) |
37 (73%) 14 (27%) | 0.692a |
33 (66%) 17 (34%) |
42 (82%) 9 (18%) | 0.060a |
Scanner | |||||||
Optima CT660 Discovery CT750 HD |
50 (49%) 53 (51%) | – | – | – |
25 (49%) 26 (51%) |
25 (48%) 27 (52%) | 0.924a |
Tube voltage (kVp) | |||||||
120 100 |
51 (50%) 52 (50%) |
25 (50%) 25 (50%) |
26 (49%) 27 (51%) | 0.924a | – | – | – |